|
|
|
|
Vol. 302, Issue 3, 1151-1157, September 2002
Institut National de la Santé et de la Recherche Médicale Unité 514, IFR 53, CHU Maison Blanche, Reims, France (S.E., D.G., S.B., J.J., E.P.); Service d'Anatomie et de Cytologie Pathologique, Hôpital Européen Georges Pompidou, Paris, France (C.D.); Service de Pneumologie, Hôpital Cochin, Paris, France (D.D.); Laboratoire Pol Bouin, Centre Hospitalier Universitaire Maison Blanche, Reims, France (D.G.); Service d'ORL pédiatrique, Hôpital d'enfants de la Timone, Marseille, France (J.-M.T.); and Département de Pharmacologie Clinique, GlaxoSmithKline, Marly-le-roi, France (C.M.-T.)
| |
Abstract |
|---|
|
|
|---|
Airway inflammation, one of the major factors leading to lung damage in
cystic fibrosis (CF) patients, is associated with an abnormal increase
in proinflammatory cytokines. In this work, we demonstrate the
increased release of the proinflammatory cytokines after
lipopolysaccharide (LPS) stimulation: human interleukin (hIL)-8 in CF
and non-CF airway xenografts, and hIL-6 and human growth-related
oncogene-
(hGRO-
), which could be only analyzed in non-CF
xenografts. Under basal conditions, we observed that hIL-8 was higher
in CF xenografts compared with non-CF. We also report the
anti-inflammatory effect of a glucocorticoid, fluticasone propionate
(FP), on CF airway epithelium using a humanized model of airway
inflammation developed in nude mice. In CF and non-CF tracheal
xenografts, airway inflammation was induced by inoculating Pseudomonas aeruginosa LPS (4 h; 1 µg/ml) in the lumen
of the xenografts. FP pretreatment (2 h; 10
8 M) followed
by P. aeruginosa LPS stimulation induced a significant reduction of LPS-induced hIL-8 release in airway liquid
collected from CF and non-CF tracheal xenografts (85 and 80%,
respectively). In non-CF tracheal xenografts, FP treatment before LPS
stimulation induced a significant decrease in hIL-6 and hGRO-
. From
these data, we suggest that FP exerts anti-inflammatory properties that may be appropriate to CF therapy, at an early stage of the disease. In
addition, these results demonstrate that the humanized airway model of
inflammation provides a relevant tool for analyzing the effects of
anti-inflammatory drugs in different diseases in which airway
inflammation is implicated.
| |
Introduction |
|---|
|
|
|---|
Cystic
fibrosis (CF) is a lethal human autosomal recessive genetic disease
caused by mutations in the CF transmembrane conductance regulator
(CFTR) gene (Riordan et al., 1989
; Rommens et al., 1989
). CF is
characterized by pancreatic insufficiency and chronic disease of the
respiratory tract, which is manifested by airway obstruction and
recurrent infections of the lung that begin early in life (Khan et al.,
1995
). CF lungs are often infected by Pseudomonas aeruginosa, which plays a major role in the development and
progression of pulmonary disease (Konstan et al., 1993
).
Inflammation is a critical component of the airway disease in CF. The
inflammatory response is characterized by a marked influx of
neutrophils into the lung and an increase in inflammatory mediators such as tumor necrosis factor-
, interleukin (IL)-1
, IL-6,
and IL-8 (Berger et al., 1991
; Konstan et al., 1993
; Wilmott et al., 1999
, 2001
). Clinical studies on nasal and bronchoalveolar lavages have
shown high neutrophil counts and increased level of a major chemoattractant, IL-8 (Balough et al., 1995
; Khan et al., 1995
; Noah et
al., 1997
), even in the absence of detectable infection. In in vitro
and ex vivo studies, we have shown an up-regulation of IL-8 in human CF
bronchial glandular cells, which could be due to a dysregulation of
nuclear factor-
B (NF-
B) transcription factor (Tabary et al.,
1998
, 2000
).
Whether inflammation is directly related to CFTR and is present very
early in CF patients, before any infection, is still the subject of
some debate. According to Armstrong et al. (1997)
, there would be no
basic defect that initiates inflammation in the absence of any initial
airway insult, although they hypothesize that a constitutive
abnormality of cytokine regulation within the CF lung could amplify and
perpetuate the inflammatory process. The current lack of knowledge on
the very early inflammation in CF infants and on the beneficial effects
of anti-inflammatory drugs is related, in part, not only to the
difficulty of investigating large populations of CF infants but also to
the absence of relevant animal models to study the condition. In
cftrm1HGU/cft
m1HGU transgenic mice raised under germ-free
conditions, we have previously shown an increased number of
inflammatory cells that did not infiltrate the airway surface
epithelium but that were more numerous in the tracheal lamina propria
of CF mice (Zahm et al., 1997
). We have also observed in human fetal
tracheae grafted in severe combined immunodeficient mice that mature CF
airways are in a proinflammatory state before exposure to an infectious
stimulus (Tirouvanziam et al., 2000
). After P. aeruginosa
infection, we observed a marked leukocyte transepithelial migration
similar to that observed in adult CF airway tissue.
One limitation of the model of mature fetal airway xenografts is
related to the difficulty involved in procuring CF human fetal tissue.
Moreover, the grafted trachea is a closed pouch that is therefore
different from the in vivo situation, and cannot be easily used to
analyze the effect of anti-inflammatory drugs. In contrast, the open
trachea model in nude mice that we recently developed using human adult
epithelial cells (Dupuit et al., 2000
) regenerates a well
differentiated airway epithelium allowing, in the present study, the
collection of tracheal liquid 1) under basal conditions; 2) after
P. aeruginosa lipopolysaccharide (LPS) stimulation; and 3)
after a 2-h pretreatment with an anti-inflammatory corticosteroid,
fluticasone propionate (FP), followed by P. aeruginosa LPS-induced inflammation. Treatment by FP has been studied previously in young CF patients and was reported not to improve lung score nor
inflammatory markers in sputum (Balfour-Lynn et al., 1997
). In patients
with severe bronchiectasis, however, inhaled FP was shown to be
effective in reducing the sputum inflammatory indices (Tsang et al.,
1998
). In both clinical studies, FP treatment was applied to patients
with a long history of bacterial infection. The protective effect of FP
in early cystic fibrosis is still unclear. In the present study, we
have examined the in vivo effect of FP on proinflammatory cytokine
production after the induction of P. aeruginosa LPS
inflammation in CF and non-CF human tracheal grafts, which had never
been previously exposed to a bacterial stimulus.
| |
Materials and Methods |
|---|
|
|
|---|
Drugs and Bacterial Stimulus.
FP was generously provided by
GlaxoSmithKline (Uxbridge, Middlesex, UK). A stock solution of FP
(10
3 M) in 99.5% ethanol was prepared. FP was
diluted in serum-free DMEM/F-12 medium (Invitrogen, Paisley, UK)
to a 10
6 M working stock solution. The stock
solutions were further diluted in DMEM/F-12 medium to achieve the
10
8 M concentration used. P. aeruginosa LPS (Calbiochem, San Diego, CA) was dissolved in
serum-free DMEM/F-12 medium to a final working solution containing 1 µg/ml of P. aeruginosa LPS.
Human Airway Tissues and Epithelial Cell Dissociation.
Samples from 12 subjects were included in the study. Human airway
tissues were obtained from nasal polypectomy of six CF patients (1
F508/G85E, 1
F508/Q1042X, 1
F508/2372 del 8, 1
F508/2894 ins AG, and 2
F508/
F508, aged 6-10 years). Control tissues were collected from bronchial cancers resections of six non-CF patients (aged 58-74 years). Immediately after nasal polypectomy or airway surgical resection, the tissues were transferred to the laboratory in
Hanks' HEPES salt (Invitrogen) supplemented with antibiotics (200 U/ml
penicillin and 200 µg/ml streptomycin). The solution also contained
colimycine (3 × 105 IU/ml) for all CF
tissues. Collected tissues were then dissociated by 0.1% pronase
(Sigma-Aldrich, St. Louis, MO) digestion for 12 h, and the
dissociated human airway epithelial cells were resuspended at a density
of 1 to 2 × 106 cells/ml in an hormonally
defined culture medium (RPMI 1640; Invitrogen) supplemented with 1 µg/ml insulin, 1 µg/ml transferrin, 10 ng/ml vitamin A, 200 U/ml
penicillin, 200 µg/ml streptomycin, 50 µg/ml gentamicin, and 2.5 µg/ml amphotericin. The dissociated human airway epithelial cells
were then inoculated into xenograft lumens (see below).
Experimental Model of Tracheal Grafts in Nude Mice.
Humanized xenografts were prepared as described previously (Dupuit et
al., 2000
). Briefly, tracheae of adult Wistar rats (weighing 220-250
g) (Charles River France, Saint-Aubin-Lès-Elbeuf, France) were
frozen at
80°C and thawed (three cycles) to remove the rat surface
epithelium. The rat tracheae were tied at their ends to sterile
polyethylene tubing and stored at
80°C until instillation with
dissociated human airway cells. After instillation, the rat tracheae
were implanted subcutaneously, two per mouse, into the flanks of
anesthetized (i.p. injection of 40 mg/kg pentobarbital sodium) nude
mice. The mice were maintained under pathogen-free conditions and the
tracheal xenografts flushed twice per week to remove cell debris from
the lumen. Tracheae were maintained for 5 weeks in the nude mice to
obtain a well differentiated human airway epithelium (Fig.
1). To develop an inflammatory state, P. aeruginosa LPS (1 µg/ml) was inoculated for a 4-h
period. The P. aeruginosa LPS and FP solutions were directly
inoculated into the lumen of the xenografts.
|
Induction of P. aeruginosa LPS Inflammation.
Inoculations were performed with a standardized volume of solution (70 µl), which covered the entire surface of the trachea and thus ensured
that all epithelial cells were in contact with inoculating solutions.
Seventy microliters of serum-free DMEM/F-12 medium (4 h) or LPS (1 µg/ml; 4 h), with or without preincubation for 2 h in
10
8 M FP, was instilled into the lumen of the
xenografts. After incubation with the different media (2 h with FP and
4 h with LPS), airway liquids were collected and the level of
secretion of proinflammatory cytokines was measured.
Staining and Histology of Tracheal Xenografts.
After
incubation with different media as described above, tracheae were
removed and embedded in optimum cutting temperature compound and stored
at
80°C. Transverse cryosections (5 µm in thickness) of tracheal
xenografts were prepared on a microtome (model 2800 Frigocut;
Reichert-Jung, NuBlock, Germany), transferred onto gelatin-coated
slides, air-dried, and stored at
20°C. These cryosections were
stained with hematoxylin-eosin and used for histological analysis.
Collection of Airway Liquid (AL) from Tracheal Xenografts
Lumens.
The developing airway epithelium in tracheae was in
constant contact with the different solutions described above.
After incubation with each of the solutions, the volume of the
recovered AL was measured and then frozen at
80°C for further
cytokine analysis.
Quantification of Cytokines by Enzyme Immunoassay.
Human
interleukin (hIL)-8, hIL-6, and growth related oncogene-
(hGRO-
)
levels were quantified in the liquids recovered from tracheal lumens
using an enzyme-linked immunosorbent assay carried out according to the
manufacturer's instructions (Biosource International, Camarillo, CA).
The limit of detection for each of these cytokines was 5, 2, and 2 pg/ml for hIL-8, hIL-6, and hGRO-
, respectively. To standardize
these results, the total protein content in the AL was quantified using
the Bradford (1976)
method. Results are expressed as picograms per
milliliter per milligram of total protein.
Statistical Analysis. Values are expressed as the mean ± S.D. for results from six animals for in vivo experiments and analyzed using nonparametric tests (Mann-Whitney and Wilcoxon tests). The level of statistically significant differences was defined as *P < 0.05 and **P < 0.01.
| |
Results |
|---|
|
|
|---|
Histology of CF and non-CF Airway Tissues.
Before dissociating
the CF and non-CF airway tissues, we characterized the percentage of
surface mucous cells and the degree of inflammation in the surface
epithelium and lamina propria by semiquantitative analysis performed on
CF and non-CF paraffin-embedded tissue sections (Table
1). Compared with CF nasal polyps, the degree of mucous hyperplasia and inflammation observed in non-CF tissues did not seem to be different. The CF and non-CF tissues exhibited enlarged interstitium with edema, capillary congestion, and
inflammatory cell infiltrates, reflecting an inflammatory state. We
also observed a large variation in the percentage of surface airway
mucous cells in both CF and non-CF tissues.
|
Histology of CF and non-CF Tracheal Xenografts before and after
P. aeruginosa LPS-Induced Stimulation.
The
histological aspect of tracheal xenografts was analyzed 5 weeks after
they had been implanted into nude mice, with microscopic images showing
that denuded rat tracheae had become repopulated with human surface
epithelial cells (Fig. 2A). We observed a
pseudostratified columnar epithelium with secretory and ciliated
differentiation (Fig. 2B) similar to that observed in human airway
tissue. We did not observe any histological difference between the CF
and the non-CF tracheal xenografts (Fig. 2, C and D). CF and non-CF tracheal xenografts were also analyzed after a 4-h incubation with
P. aeruginosa LPS. In the presence of LPS (4 h; 1 µg/ml), no increase was observed in the number of mucous cells in stimulated CF
and non-CF tracheal xenografts compared with unstimulated controls. Furthermore, compared with control, no efflux of host inflammatory cells through the airway epithelium was observed after a 4-h exposure of the xenografts to LPS (Fig. 2, E and F).
|
Collection of Human AL from non-CF and CF Tracheal Xenografts.
At the beginning of the experiment, the tracheal lumen was inoculated
with a standardized volume (70 µl) of solution that filled entirely
the lumen and therefore covered the human airway epithelial cells
developing on the surface of the rat trachea. After a 4-h incubation
period, we collected the human AL from non-CF and CF xenografts and
measured the volume obtained. Under basal conditions, we observed a
significant (P < 0.01) difference in AL volume between
CF and non-CF tracheal xenografts. The volume of AL in non-CF
xenografts was 1.6-fold higher on average than that in CF xenografts
(Fig. 3). After stimulation with LPS (4 h; 1 µg/ml), an increase of AL volume in CF as well as in non-CF xenografts was observed but the difference was not significant. After
pretreatment with FP (2 h; 10
8 M) followed by
P. aeruginosa LPS (4 h; 1 µg/ml) incubation, the mean of
AL volume in non-CF and CF tracheal xenografts was similar to that
collected in control xenografts.
|
Cytokine Content of AL from CF and non-CF Grafts.
The lumen of
fully differentiated CF and non-CF xenografts was first inoculated with
a 70-µl volume of serum-free DMEM/F-12 medium. After a 4-h
incubation, the human AL was collected and the level of secretion of
proinflammatory cytokines measured. For this control condition, the
hIL-8 secretion was significantly (P < 0.05) higher
with a 6-fold increase in CF compared with non-CF tracheal xenografts
(Fig. 4).
|
|
8
M) followed by stimulation with P. aeruginosa LPS (4 h; 1 µg/ml) resulted in a decrease of hIL-8 secretion in CF and
non-CF tracheal xenografts, of 85 and 80% respectively, compared with
tracheal xenografts exposed to P. aeruginosa LPS alone. The
level of hIL-8 after pretreatment with FP was approximately the same as
that recorded under control conditions as described above
(Fig. 5).
Due to the small volume of AL recovered from tracheal CF xenografts, we
could only measure hIL-8 secretion in the AL from these grafts, and not
hIL-6 and hGRO-
as well, which was possible in non-CF tracheal
xenografts. After P. aeruginosa LPS stimulation, the
secretion of hIL-6 and hGRO-
in non-CF tracheal xenografts was
significantly (P < 0.01) increased (953.9 ± 91.5 and 10,068.7 ± 963.2 pg/ml/mg of protein, respectively) compared
with that measured in non-CF tracheal xenografts exposed to control
culture medium (277.5 ± 42.9 and 4,252.6 ± 483.2 pg/ml/mg
of protein, respectively).
After FP pretreatment of non-CF xenografts, the levels of hIL-6 and
hGRO-
secretion were significantly (P < 0.01)
reduced (445.3 ± 92.4 and 4125.7 ± 1463.1 pg/ml/mg of
protein, respectively) compared with that measured after P. aeruginosa LPS stimulation alone.
| |
Discussion |
|---|
|
|
|---|
In the present study, we analyzed the in vivo effects of P. aeruginosa LPS-induced inflammatory stimulation on cytokine secretion by collecting luminal tracheal fluids from humanized airway xenografts before and after a 2-h pretreatment with FP. We first analyzed the control (basal) inflammatory state in airway epithelium from the humanized xenografts from both CF and non-CF. The xenografts had not previously been exposed to bacteria
Under basal condition, the results demonstrated that hIL-8 secretion is
significantly higher in CF tracheal xenografts compared with non-CF
tracheal xenografts. In contrast, the volume of AL collected was
significantly lower in CF tracheal xenografts. After stimulation with
P. aeruginosa LPS, we observed an increase in the level of
hIL-8 secretion in CF and non-CF tracheal xenografts compared with
xenografts exposed to control culture medium alone. FP was shown to
decrease the level of LPS-induced hIL-8 secretion in CF and non-CF
xenografts compared with xenografts exposed to LPS alone. These results
are consistent with the increased level of basal IL-8 secretion
identified in cultures of CF airway epithelial cells (Kammouni et al.,
1997
; Tabary et al., 1998
, 1999
; Bonfield et al., 1999
) and in CF
bronchoalveolar fluids (Balough et al., 1995
; Khan et al., 1995
; Noah
et al., 1997
). More recently, we used an in vivo model of human CF
fetal trachea grafted into severe combined immunodeficient mice, and we
demonstrated that the AL IL-8 content from CF grafts was increased
compared with non-CF grafts (Tirouvanziam et al., 2000
). The
up-regulation of IL-8 in CF cells may be explained by a dysregulation
of the complex NF-
B and its inhibitor factor I
B
(Tabary et
al., 2000
), occurring early in the development of CF airways before the
onset of any infection.
The volume of AL collected from CF xenografts was lower than that
measured in non-CF xenografts. This result is supported by the study of
Zhang et al. (1996)
where a higher rate of fluid absorption in CF has
been also reported in in vivo human bronchial xenografts. These
findings coupled with our results suggest a mechanism by which
increased fluid absorption in CF airway epithelia leads to dehydration
of mucus and impaired mucociliary clearance. They also support the
recent results from Tarran et al. (2001a
,b
), describing a
profound decrease in nasal airway surface liquid volume of CF mice.
These authors also observed an increase in the size and number of
secretory cells in the tissues they examined. We did not observe such
changes in the airway epithelium of CF xenografts, which seemed to be
histologically unaffected compared with non-CF tracheal xenografts.
Furthermore, despite the heterogeneity that we observed on the native
tissue, no morphological differences in epithelium developed in
tracheal xenografts were observed. The similar histological appearance
between the CF and the non-CF airway xenografts is in agreement with
the notion that significant disease is not seen in CF lung before
infections and already reported in a previous article (Tirouvanziam et
al., 2000
). When CF tracheal xenografts were challenged with
P. aeruginosa LPS, we observed neither migration of
inflammatory cells, mucus hypersecretion, nor epithelial desquamation.
In contrast to other studies, we inoculated only a low P. aeruginosa LPS concentration (1 µg/ml) in the xenograft lumen
and for only a short period of time (4 h). The LPS concentration used
in the present study was approximately equal to that reported in
bronchoalveolar lavage in adult respiratory distress syndrome (1-1.5
pg/ml) (Martin et al., 1994
). From the LPS concentrations reported in
the literature for bronchoalveolar lavage, we could hypothesize that,
for pathological situations, the LPS concentration approximates 1 µg/ml. In our study, contrary to mice models challenged with P. aeruginosa in agar beads (Wilmott et al., 2000
) or human airway
grafts infected with P. aeruginosa (Tirouvanziam et al.,
2000
), we did not observe a leukocyte transepithelial migration.
Although Tirouvanziam et al. (2000)
reported a proinflammatory state
(increased IL-8) without any histological difference in CF and non-CF
grafts, they have shown that a recruitment of inflammatory cells and
epithelial cell detachment were observed when the CF grafts were
exposed to P. aeruginosa (not seen in non-CF grafts). We
hypothesize that we did not observe an inflammatory cell transmigration in CF grafts after LPS stimulation because the soluble virulence factors like LPS are not able to induce leukocyte transepithelial migration and/or epithelial exfoliation as do alive P. aeruginosa bacteria. The short incubation period (4 h) and
relatively low concentration of P. aeruginosa LPS used in
our study may likely explain the absence of leukocyte migration despite
the induction of proinflammatory mediators. Our experimental conditions
probably mimic a situation of early and mild airway inflammation.
For the first time, a model of mild airway inflammation in well
differentiated human airway epithelium developed in nude mice is
described. This model allowed us to analyze the effects of an
anti-inflammatory molecule, fluticasone propionate, on proinflammatory cytokine release. After FP treatment, we demonstrated a decrease of
hIL-8 secretion induced by P. aeruginosa LPS in the AL
collected from CF and non-CF grafts. In fact, airway inflammation
through proinflammatory cytokines is a central feature of the
pathophysiology of CF patients and represents a major challenge to the
treatment of CF patients. Glucocorticoids are well known as very potent anti-inflammatory drugs. FP is one of the more efficient molecules able
to reduce the inflammatory response and has been shown to attenuate
inflammation in several respiratory inflammatory diseases such as
asthma, nasal polyposis, rhinitis, and acute sinusitis (Scadding,
2000
). FP possesses highly lipophilic properties that allow the drug to
attain high pulmonary concentrations. Moreover, the high affinity of FP
with the glucocorticoïd receptor permits FP to have a prolonged
anti-inflammatory effect. In vitro studies have shown that FP is very
efficient in inhibiting the release of proinflammatory mediators from
human bronchial epithelial cells (Wang et al., 1997
; Ek et al., 1999
).
FP has also been reported to inhibit more potently granulocyte
macrophage colony-stimulating factor from nasal polyp epithelial cells
than other glucocorticoids such as budesonide, beclomethasone
dipropionate, and triamcinolone acetonide (Mullol et al., 2000
).
Many investigations have been made into the molecular and cellular
actions of steroids. The anti-inflammatory action of corticosteroids is
shown to be mediated by the inhibition of activation of
transcription factors such as activator protein-1 and NF-
B (Adcock
and Caramori, 2001
), which are implicated in the transcription
of inflammatory genes. We have recent in vitro data that demonstrate
that FP can suppress NF-
B activation via inhibition of I
B
kinases, that is, via activation of I
B
, the major inhibitor of
NF-
B (Escotte et al., 2001
).
In adult CF patients, short-term fluticasone therapy had no evident
effect on clinical and sputum parameters (Dauletbaev et al., 1999
), and
other studies showed that young CF patients did not improve symptom
scores, lung function, or sputum inflammatory markers when treated with
inhaled FP compared with placebo (Balfour-Lynn et al., 1997
).
One possible explanation is that, due to sputum hyperviscosity in CF
patients, the penetration of FP through the viscous mucus to the
mucosal tissue is very difficult. In the present study, grafts were
rinsed two times per week to remove cellular debris and this is likely
to have also removed some of the mucus. Under such conditions, FP could
access directly and penetrate into the epithelial cells.
In conclusion, our results support the use of models such as that of human CF and non-CF airway grafts to investigate the early inflammatory status of the airway epithelium and the response to bacterial stimuli. This study confirms that inflammation occurs very early in CF airways and demonstrates that FP may prevent the release of inflammatory mediators after P. aeruginosa LPS-induced inflammation.
| |
Acknowledgments |
|---|
We thank the team of Service d'ORL pédiatrique, Hôpital d'enfants de la Timone (Marseille, France), and the team of Service d'Anatomie et de Cytologie Pathologiques, Hôpital Européen Georges Pompidou (Paris, France), for cooperation in providing CF and non-CF respiratory tissues.
| |
Footnotes |
|---|
Accepted for publication April 25, 2002.
Received for publication January 22, 2002.
This work was supported by INSERM, Association Vaincre la Mucoviscidose, and GlaxoSmithKline. S.E. is a predoctoral fellow of the French Association Vaincre la Mucoviscidose.
DOI: 10.1124/jpet.102.033407
Address correspondence to: Edith Puchelle, INSERM U514, IFR 53, Université de Reims, CHU Maison Blanche, 45, rue Cognacq-Jay, 51092 Reims Cedex, France. E-mail: epuche{at}worldnet.fr
| |
Abbreviations |
|---|
CF, cystic fibrosis;
CFTR, cystic fibrosis
transmembrane conductance regulator;
IL, interleukin;
NF-
B, nuclear
factor-
B;
LPS, lipopolysaccharide;
FP, fluticasone propionate;
DMEM, Dulbecco's modified Eagle's medium;
AL, airway liquid;
hIL, human
interleukin;
hGRO-
, human growth related oncogen-
.
| |
References |
|---|
|
|
|---|
B kinase
expression in human bronchial epithelial cells. Twenty-fourth European Cystic Fibrosis Conference, Vienna, Austria, Abstract S5.
B kinase
pathway in response to extracellular NaCl content.
J Immunol
164:
3377-3384
B activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells.
Am J Pathol
155:
473-481
.
Eur Respir J
10:
834-840[Abstract].This article has been cited by other articles:
![]() |
A. Linden, M. Laan, and G. P. Anderson Neutrophils, interleukin-17A and lung disease Eur. Respir. J., January 1, 2005; 25(1): 159 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Escotte, O. Tabary, D. Dusser, C. Majer-Teboul, E. Puchelle, and J. Jacquot Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-{beta} kinase pathway Eur. Respir. J., April 1, 2003; 21(4): 574 - 581. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||